abstract background individual studies have assessed the impact of standard prophylactic therapy with 5-hydroxytryptamine receptor antagonists (5-ht3ras) for chemotherapy-induced nausea and vomiting (cinv) on cost and utilization, but no synthesis of the findings exists.